LEXINGTON, Mass., July 27, 2018 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the developmentand commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will release its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.S. financial markets open. The
To access the live conference call, please dial (888) 346-6389 from the United States or 1 (412) 317-5252 from other locations, shortly before 8:30 a.m. EDT. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the PDL1/VISTA antagonist CA-170, and the PDL1/TIM3 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.
View original content:http://www.prnewswire.com/news-releases/curis-to-release-second-quarter-financial-results-and-hold-conference-call-on-august-2-2018-300687660.html
SOURCE Curis, Inc.
Subscribe to our Free Newsletters!